Atogepant 60 mg

Phase 3

AbbVie Inc. (ABBV)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Migraine

LLYGalcanezumab

Phase 3

View Full Landscape

Drug Information

Target Indication

Chronic Migraine

Clinical Trial

NCT04437433

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/11/2023

Aquipta

Aquipta is indicated for: - acute treatment of migraine with or without aura in adults - prophylaxis of migraine in adults who have at least 4 migraine days per month.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ABBV

AbbVie Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

AcalabrutinibPhase 3

Chronic Lymphocytic Leukemia

Bimatoprost (SR)Phase 3

Open-Angle Glaucoma

etanerceptPhase 3

Moderate to Severe Plaque Psoriasis

EtentamigPhase 3

Multiple Myeloma

ElagolixPhase 3

Polycystic Ovary Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts